NRX leading biotech plays in 2024
NRX Nurexone Biologic leading biotech plays in 2024 with several recent developments from newly uplisting on the OTC, leasing agreement until 2028 of a state-of-the-art facility on a University campus in Israel to beginning clinical trials shortly. Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.